Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib.

Blood Cancer J · 2023 · PMC10495334 · PMID 37696829

Europe PMC DOI

hedged sentence

0.1900

closest p · 3.8× alpha

0.1900

boldest claim

The sentences

did not reach statistical significancep = 0.19not close (p > 0.1)

Patients with low IVKI had a numerically higher rate of transformation to blast crisis than patients with high IVKI, but this did not reach statistical significance (7.7% vs 3%, OR 2.71, 95% CI 0.65–10.39, p = 0.19, Supplementary Fig. 3C ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.